Chronic urticaria (spontaneous & inducible)

What changes during this transition

Chronic urticaria looks dermatologic but is mechanistically immunologic. Mast cells in the skin release histamine, leukotrienes, platelet-activating factor, and cytokines on a hair trigger; the wheal-and-flare lasts under twenty-four hours per individual lesion but the disease itself can persist for years. Around thirty to fifty percent of CSU is autoimmune in the type IIb sense — IgG autoantibodies against FcεRI (the high-affinity IgE receptor) or against IgE itself, detectable on CU-Index or basophil activation testing where those are clinically available. Another subset is type I autoimmune (IgE autoantibodies against self-antigens like thyroid peroxidase or IL-24). Hashimoto's thyroiditis overlaps CSU in roughly twenty-five percent of cases, and a workup that captures TSH, free T4, TPO antibodies, and thyroglobulin antibodies catches the comorbidity that changes long-term management. The 2021 EAACI/GA²LEN/EuroGuiDerm/APAAACI international guideline (and the AAAAI/ACAAI 2014 US update) sets a stepwise standard of care that the peptide-curious population needs to understand before any adjunct conversation. Step one is a second-generation non-sedating H1-antihistamine at standard dose. Step two is up-titration of the same antihistamine to as much as four times the standard dose; this is guideline-endorsed and underused. Step three — and this is the paradigm shift — is omalizumab (Xolair), a monoclonal anti-IgE antibody FDA-approved for CSU in 2014 on the strength of the ASTERIA I, ASTERIA II, and GLACIAL trials. Three hundred milligrams subcutaneously every four weeks produces complete or near-complete response in a majority of antihistamine-refractory patients within twelve to twenty-four weeks. Step four is cyclosporine (off-label, with blood pressure and renal monitoring) or add-on biologics. The frontier is moving fast. Ligelizumab (a higher-affinity anti-IgE) ran the PEARL Phase 3 program with mixed results. Dupilumab (anti-IL-4Rα) hit primary endpoints in LIBERTY-CUPID Study A and Study C and received FDA approval for CSU in April 2025, giving antihistamine-refractory patients a second biologic mechanism. Barzolvolimab — an anti-KIT monoclonal that depletes tissue mast cells rather than blocking a downstream cytokine — is in Phase 3 and represents the cleanest mechanistic shot at CIndU subtypes (cold, cholinergic, symptomatic dermographism) where anti-IgE biologics are less effective. BTK inhibitors remibrutinib (REMIX Phase 3) and fenebrutinib are also in late-stage trials. What none of this looks like is a peptide protocol. The disease driver is mast cell hyper-reactivity (sometimes IgE-mediated, sometimes autoimmune-IgG-mediated, sometimes idiopathic), and the targeted biologics now reach upstream of the mast cell, or deplete it outright. Peptides marketed for inflammation generally — BPC-157 for mucosal repair, KPV for IBD-style mucocutaneous inflammation, thymosin alpha-1 for immune modulation in chronic viral disease — do not address the FcεRI cascade, the IgG autoantibody population, or mast cell granule release. The community framing that pulls peptides into the chronic-urticaria conversation is almost entirely off-target relative to the actual mechanism, and the editorial answer here is honesty about the gap. A separate red-flag concern: angioedema without urticaria, especially if antihistamines and epinephrine don't touch it, is suspicious for hereditary or acquired C1-inhibitor-mediated angioedema (HAE/AAE) — bradykinin-driven, not histamine-driven, and a fundamentally different disease with its own targeted therapies (C1-INH concentrate, icatibant, lanadelumab, berotralstat). Mistaking HAE for CSU and treating it with antihistamines is dangerous; a CSU-track workup that includes C4 (and, if low, C1-INH level and function) is the standard ruling-out step.